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Abstract
Background: Severe obesity is associated with an increased risk of coronary artery disease (CAD). Bariatric surgery
is an effective procedure for long term weight management as well as reduction of comorbidities. Preoperative
evaluation of cardiac operative risk may often be necessary but unfortunately standard imaging techniques are
often suboptimal in these subjects. The purpose of this study was to demonstrate the feasibility, safety and utility
of transesophageal dobutamine stress echocardiography (TE-DSE) using an adapted accelerated dobutamine
infusion protocol in severely obese subjects with comorbidities being evaluated for bariatric surgery for assessing
the presence of myocardial ischemia.
Methods: Subjects with severe obesity [body mass index (BMI) >40 kg/m
2] with known or suspected CAD and
being evaluated for bariatric surgery were recruited.
Results: Twenty subjects (9M/11F), aged 50 ± 8 years (mean ± SD), weighing 141 ± 21 kg and with a BMI of 50 ± 5 kg/
m
2 were enrolled in the study and underwent a TE-DSE. The accelerated dobutamine infusion protocol used was well
tolerated. Eighteen (90%) subjects reached their target heart rate with a mean intubation time of 13 ± 4 minutes. Mean
dobutamine dose was 31.5 ± 9.9 ug/kg/min while mean atropine dose was 0.5 ± 0.3 mg. TE-DSE was well tolerated by
all subjects without complications including no significant arrhythmia, hypotension or reduction in blood arterial
saturation. Two subjects had abnormal TE-DSE suggestive of myocardial ischemia. All patients underwent bariatric
surgery with no documented cardiovascular complications.
Conclusions: TE-DSE using an accelerated infusion protocol is a safe and well tolerated imaging technique for the
evaluation of suspected myocardial ischemia and cardiac operative risk in severely obese patients awaiting bariatric
surgery. Moreover, the absence of myocardial ischemia on TE-DSE correlates well with a low operative risk of
cardiac event.
Background
Severe obesity is associated with multiple comorbidities
and an increased risk for coronary artery disease (CAD)
since many risk factors for CAD are present in obese
patients. Bariatric surgery is probably the most effective
procedure for long term weight management as well as
reduction of comorbidities in this population [1]. It also
increases survival [2]. Preoperative evaluation of sus-
pected myocardial ischemia and cardiac operative risk
may be necessary in these high risk patients but unfor-
tunately standard imaging techniques are often subopti-
mal in severely obese subjects [3]. Hansen et al. have
reported that the accuracy of thallium-201 single-photon
emission computed tomography is reduced in obesity
[4]. On the other hand, transthoracic dobutamine stress
echocardiography has a high sensitivity and specificity
for the detection of myocardial ischemia [5]. This
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any medium, provided the original work is properly cited.imaging technique is also used for the stratification of
preoperative risk of cardiac events [6,7]. Unfortunately
standard transthoracic stress echocardiography is often
suboptimal in obese patients because of paucity of
echogenicity.
Transesophageal echocardiography provides superior
quality cardiac imaging and transesophageal dobutamine
stress echocardiography (TE-DSE) compares favourably
with myocardial scintigraphy for the detection of myo-
cardial ischemia in non severely obese patients [8].
A study of 341 obese patients body mass index (BMI) >
27,5 kg/m
2 demonstrated that transesophageal echocar-
diography is a safe and well tolerated procedure in this
population [9]. Moreover, in a study evaluating 23
severely obese patients, Madu showed that TE-DSE is a
useful and safe method for the detection of CAD [10]
while a small study in 7 severely obese patients revealed
that TE-DSE is a valid non-invasive imaging technique
for evaluating cardiac risk before bariatric surgery [11].
The purpose of this study was to demonstrate the safety
and reliability of a new adapted transoesophageal accel-
erated dobutamine infusion protocol including atropine
for assessing cardiac ischemia.
Methods
Twenty severely obese patients (BMI > 40 kg/m
2)w e r e
recruited between March 2006 to June 2007 from the
bariatric surgery preoperative evaluation clinic. All
patients were considered at high cardiovascular risk
because of known CAD or suspected CAD on the basis
of an abnormal resting ECG or the presence of at least
2 risk factors for CAD (systemic hypertension, diabetes
mellitus, smoking, dyslipidemia, positive family history
of premature CAD or sleep apnea). Exclusion criteria
included: recent acute coronary syndrome, uncompen-
sated heart failure, uncontrolled ventricular or supraven-
tricular arrhythmias, oral or oesophageal pathology,
uncontrolled systemic hypertension or significant valvu-
lar heart disease. Twenty patients underwent a TE-DSE.
Beta-blockers were stopped 48 hours before the stress
test. The study was approved by the local hospital ethics
committee in accordance with the Helsinki declaration
and subjects gave signed informed consent.
TE-DSE protocol
TE-DSE was performed with a commercially available
echocardiography machine (Sonos 5500, Hewlett-Pack-
ard) using a multiplane probe. Antianginal medications
were discontinued for at least 24 hours prior the study.
Studies were performed after an overnight fast with
patients in the left lateral decubitus position. Topical
oropharyngeal anesthetic spray was used and light seda-
tion was achieved with the use of intravenous midazo-
lam (Midazolam Injection, Sandoz, Canada) or diazepam
(Diazemul, Pfizer, Canada) before the introduction of
the transesophageal probe. All patients received supple-
mental oxygen through nasal prongs. Oxygen saturation
was continuously monitored throughout the procedure
using pulse oxymetry. A continuous 12-lead electrocar-
diogram monitored for arrhythmias or ST-segment
modifications suggestive of myocardial ischemia. Blood
pressure was measured non-invasively every 3 minutes
throughout the procedure.
Dobutamine was intravenously infused using an accel-
erated protocol with a starting dose of 10 ug/kg/min and
increased every 2 minutes to 20, 30 and 40 ug/kg/min.
Atropine sulphate was given intravenously in increments
of 0.2 mg from the second stage of the dobutamine infu-
sion (20 ug/kg/min) until 85% of the maximal heart rate
(i.e. 220-age) was reached or up to a maximum of 1 mg.
Images were obtained at each stage in the following
sequence: 1) midesophageal four-chamber view at 0°, 2)
midesophageal two-chamber view at 60°, 3) midesopha-
geal three-chamber view at 120° and, 4) transgastric mid-
papillary short-axis view at 0° (see additional file 1, 2, 3,
4, 5, 6, 7, &8). Left ventricular wall motion was qualita-
tively assessed and myocardial ischemia was documented
if a new wall motion abnormality appeared. Echocardio-
graphies were reviewed by two echographists who were
blinded to the results of the TE-DSE.
Patient’s charts were reviewed for the presence of CAD
risk factors, current medications and recent blood chem-
istry. The outcome following bariatric surgery, including
the presence of perioperative cardiovascular complica-
tions, was noted. Cardiovascular complications were
assessed for 30 minutes post imaging procedures. Tropo-
nin levels were measured 24-hrs post bariatric surgery.
Statistical analysis
Population characteristics and echocardiographic data
are reported as mean ± standard deviation or a propor-
tion of the sample size.
Results
The accelerated dobutamine infusion protocol used was
well tolerated. Eighteen (90%) subjects reached their tar-
get heart rate with a mean intubation time of 13 ± 4
minutes. Mean dobutamine dose was 31.5 ± 9.9 ug/kg/
min while mean atropine dose was 0.5 ± 0.3 mg. Twenty
patients (55% female) with a mean age of 50 ± 8 years
and mean BMI of 50 ± 5 kg/m
2 were recruited. Only 1
patient was known to have CAD (previous coronary
bypass surgery) but the majority of subjects (74%) had a
least 3 risk factors for CAD and an abnormal metabolic
profile (Table 1). Six patients (30%) had abnormal rest-
ing ECGs showing abnormal Q waves (2 patients),
abnormal rightward axis (1 patient) or non-specific con-
duction abnormalities (3 patients).
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complications including no significant arrhythmia, hypo-
tension or reduction in blood arterial saturation. No
patient develops clinical pneumonia-induced aspiration.
Sedatives were administered to ensure subject’sc o m f o r t
(midazolam 10 ± 7 mg or diazepam 15 ± 6 mg). Seven-
teen patients (85%) required atropine to reach their tar-
get heart rate. Only 7 subjects (35%) had adequate
transgastric images for the evaluation of left ventricular
wall motion but transesophageal images were of diag-
nostic quality in all patients. At peak dose, 3 subjects
complained of symptoms suggestive of myocardial ische-
mia. One patient developed ECG changes suggestive of
myocardial ischemia (ST segment depression ≥ 1m m )
and 2 patients had new left ventricular wall motion
abnormalities compatible with myocardial ischemia
(hypokinesia) (Table 2). Ischemic threshold was docu-
mented in both patients.
Discussion
The main finding of this study is that TE-DSE using an
accelerated dobutamine protocol is a safe and well toler-
ated imaging technique for the evaluation of suspected
myocardial ischemia in severely obese patients awaiting
bariatric surgery.
In this study, we used an accelerated protocol for the
infusion of dobutamine. The purpose was to minimize
probe insertion time. Our probe insertion time of 13 ±
4 min compares favourably with previous studies. In the
study by Madu et al [10], probe insertion time was 29 ±
7 min and significant hypotensive response was noted in
43% of their subjects. Our accelerated protocol was very
well tolerated with no significant hypotension or reduc-
tion in oxygen saturation and 90% of our patients
reached their target heart rate. Pastorius et al. demon-
strated the tolerability of an accelerated dobutamine
infusion in standard transthoracic dobutamine echocar-
diography [12]. To the best of our knowledge, the pre-
sent study is the first to have used an accelerated
protocol in TE-DSE.
Obesity has become an epidemic condition around the
world and is associated with increased risk of CAD and
risk factors for CAD (i.e. systemic hypertension, dia-
betes, dyslipidemia and sleep apnea) [13,14]. In the Uni-
t e dS t a t e s ,t h ep e r c e n t a g eo fa d u l t sw h oa r eo b e s e( B M I
>3 0k g / m
2) was estimated at 23.9% in 2005 with
approximately 4.8% considered to be severely obese
(BMI > 40 kg/m
2) [14]. The BMI subgroups experien-
cing the most rapid growth are ≥ 35 or ≥ 40 kg/m
2 [13].
Bariatric surgery induces long term significant weight
loss with a meta-analysis showing that the majority of
patients with diabetes, dyslipidemia, systemic hyperten-
sion or obstructive sleep apnea experience complete
Table 1 Study population characteristics (n = 20)
Age (years) 50 ± 8
Men/Women 9 (45%)/11 (55%)
Weight (kg) 141 ± 21
BMI (kg/m2) 50 ± 5
Known CAD 1 (5%)
Risk factors for CAD
Systemic hypertension 15 (75%)
Diabetes mellitus 13 (65%)
Smoking (active or past) 8 (40%)
Dyslipidemia 13 (65%)
Positive family history for CAD 3 (15%)
Sleep apnea 15 (75%)
Abnormal resting ECG 6 (30%)
Medications
Aspirin 10 (50%)
Beta-blockers 5 (25%)
Calcium channel blockers 5 (25%)
ACEI/ARB 12 (60%)
Statins 6 (30%)
Fibrates 2 (10%)
Ezetimide 2 (10%)
Nitrates 1 (5%)
Diuretics 8 (40%)
Oral hypoglycaemic agents 9 (45%)
Insulin 5 (25%)
Baseline blood chemistry
Fasting blood glucose (mmol/L) 7.4 ± 3,5
HbA1c (%) 6.9 ± 1.5
Total cholesterol (mmol/L) 4.7 ± 1.4
LDL-cholesterol (mmol/L) 3.1 ± 1.2
HDL-cholesterol (mmol/L) 1.3 ± 0.2
Total cholesterol/HDL cholesterol 3.7 ± 1.3
Triglycerides (mmol/L) 2.0 ± 1.3
ACEI = angiotensin-converting enzyme inhibitors, ARB = angiotensin receptor
blockers, BMI = boby mass index, CAD = coronary artery disease, HbA1c =
glycated haemoglobin (normal range 4-6%), HDL = high-density lipoprotein,
LDL = low-density lipoprotein
Table 2 Transesophageal dobutamine echocardiography
results (n = 20)
Resting HR (bpm) 78 ± 12
Peak dose HR (bpm) 147 ± 12
Resting SBP (mmHg) 140 ± 19
Peak dose SBP (mmHg) 168 ± 36
Resting DBP (mmHg) 83 ± 9
Peak dose DPB (mmHg) 89 ± 15
Symptoms of myocardial ischemia 3 (15%)
ECG changes suggestive of ischemia 1 (5%)
New LV wall motion abnormalities 2 (10%)
DBP = diastolic blood pressure, HR = heart rate, LV = left ventricular, SBP =
systolic blood pressure
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dies have showed reduced cardiovascular mortality fol-
lowing bariatric surgery [2,15]. Preoperative evaluation
prior to surgery is important in high risk patients. Of
note, specific approaches regarding pre-operative risk
stratification in severely obese patients have not been
addressed in previous European or American Guidelines.
The only tentative algorithm has been published earlier
[3]. This is of importance since older and sicker patients
are now being considered for bariatric surgery as in our
study. Specific contraindications to bariatric surgery are
few [3]. A recent study of 52 patients with known clini-
cal CAD undergoing bariatric surgery reported a trend
for more nonfatal cardiac events in comparison to
patients without CAD [16]. Also, ejection fraction may
be reduced in severely obese patients secondary to
hibernating myocardium due to significant CAD or the
presence of diabetic or obesity cardiomyopathy [3,17].
Thus, careful selective cardiac investigation to optimize
medical management prior surgery and to identify
potential perioperative or postoperative complications
may be necessary [3]. However, the most appropriate
method to assess the presence of CAD in this popula-
tion remains uncertain. The role of alternative techni-
ques in the assessment of pre operative risk such as
adenosine magnetic resonance imaging or coronary
computed tomography is severely obese patients is not
known. We undertook the present study to demonstrate
the feasibility and safety of an adapted TE-DSE in
severely obese subjects.
Obese patients have a higher prevalence of systemic
hypertension, CAD, and sleep apnea which could poten-
tially increase the risk of complications during transoeso-
phageal echocardiography. Also higher doses of sedatives
are often necessary in this population which could
further increase the risk of complications, including oxy-
gen desaturation. In a study comparing transesophageal
echocardiography in 341 obese subjects (mean BMI 41
kg/m
2) with 323 nonobese subjects, Garimella et al
showed that the frequency of complications did not differ
between both groups. Oxygen desaturation was infre-
quent when supplemental oxygen was used [9]. Another
study demonstrated that the frequency of complications
seen during TE-DSE in obese subjects (mean BMI 39 kg/
m
2) with suspected CAD were not significantly different
from those of nonobese individuals [18]. In our study,
despite a higher BMI (mean BMI 50 kg/m
2)a n dt h eu s e
of large doses of sedatives, there were no complications
including no significant hypotension or oxygen desatura-
tion reinforcing the safety of TE-DSE in severely obese
subjects. Only 35% of our subjects had adequate trans-
gastric imaging. We propose that severe abdominal obe-
sity might displace the stomach in a more anterior
position resulting in altered probe contact. In fact, in a
previous study of TE-DSE in nonobese subjects, 8% of
patients had poor transgastric echocardiographic images
related to the presence of hiatal hernia or gastroesopha-
geal disease [19].
Assuming equal technical competence, the debate per-
sists regarding which imaging modality between stress
echocardiography and stress myocardial perfusion ima-
g i n gi st h em o s ta c c u r a t ef o rt h ed i a g n o s i so fC A D .I n
nonobese populations, TE-DSE has showed to be a useful
technique in the evaluation of CAD with a sensitivity of
82 to 92% and a specificity of 93% when compared with
coronary angiography [19,20]. In patients with poor ima-
ging windows, it has been demonstrated that TE-DSE
offers better sensitivity, specificity and positive predictive
value compared to transthoracic imaging [21]. In a study
evaluating 23 severely obese patients with chest pain with
TE-DSE, Madu showed that 7 of 9 patients with positive
TE-DSE had objective confirmatory evidence of CAD
either by cardiac catheterization or clinical event [10].
There are fewer reports regarding the accuracy of myo-
cardial perfusion imaging in severely obese patients. One
study [4] using Thallium-201 myocardial perfusion ima-
ging demonstrated lower accuracy in patients with BMI >
30 kg/m
2, and comparing single photon emission com-
puted tomography (SPECT) results with positron emis-
sion tomography (PET), discordance was encountered
with greater frequency in obese patients, mostly in the
territories supplied by left anterior descending or right
coronary arteries, as a result of more prominent attenua-
tion artefacts [22]. In a study by Bhat et al., 7 severely
obese patients were evaluated with TE-DSE prior to bar-
iatric surgery to determine cardiac risk. Six of 7 patients
had no evidence of ischemia. All patients successfully
underwent bariatric surgery without cardiac events [11].
This compares to our study in which all patients, includ-
ing both patients with abnormal TE-DSE, have under-
gone surgery without cardiovascular complications. Most
patients in our study would be assigned to a low preo-
perative risk group, which is somewhat in agreement
with the high normalcy rate of TE-DSE. Only one patient
in our study underwent coronary angiogram. This patient
was known to have atypical chest pain and TE-DSE was
negative. Angiography was within normal limits in this
patient.
There are some limitations inherent to our study.
Without information on coronary arterial wall and
lumen, for example by means of intravascular ultra-
sound or quantitative coronary angiography, it is specu-
lative to comment on the accuracy of TE-DSE regarding
the presence of clinically significant CAD in these
patients (namely 50% stenosis on coronary angiography).
At the very least, a larger study including more patients
with coronary angiography should be performed before
we can conclude on the validity of TE-DSE for the
Legault et al. Cardiovascular Ultrasound 2010, 8:30
http://www.cardiovascularultrasound.com/content/8/1/30
Page 4 of 6diagnosis of CAD in patients with severe obesity. Also
since this study included only 20 patients, a larger study
should be performed to assess and confirm the safety of
this accelerated protocol of TE-DSE before its wide
implantation in clinical practice.
Conclusions
In conclusion, TE-DSE with an accelerated protocol is a
safe and well tolerated imaging technique for the evalua-
tion of suspected myocardial ischemia and cardiac
operative risk in severely obese patients awaiting baria-
tric surgery. Moreover, the absence of myocardial ische-
mia on TE-DSE correlates well with a low operative risk
of cardiac event.
Additional material
Additional file 1: Video1 Rest 2 chamber. 2 chamber view TE-DSE
(rest).
Additional file 2: Video2 30 mg 2 chamber. 2 chamber view TE-DSE
(30 mg).
Additional file 3: Video3 Rest 3 chamber. 3 chamber view TE-DSE
(rest).
Additional file 4: Video4 30 mg 3 chamber. 3 chamber view TE-DSE
(30 mg).
Additional file 5: Video5 Rest 4 chamber. 4 chamber view TE-DSE
(rest).
Additional file 6: Video6 30 mg 4 chamber. 4 chamber view TE-DSE
(30 mg).
Additional file 7: Video7 Rest short axis. short axis view TE-DSE (rest).
Additional file 8: Video8 30 mg short axis. short axis view TE-DSE
(30 mg).
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